Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 2

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

DNA damage and repair in lymphocytes of normal individuals and cancer patients: studies by the comet assay and micronucleus tests.

100%
Palyvoda O., Polańska J., Wygoda A., Rzeszowska-Wolny J.
|
2003
|
vol. 50
|
issue 1
181-190
EN
A population study is reported in which the DNA damage induced by γ-radiation (2 Gy) and the kinetics of the subsequent repair were estimated by the comet and micronucleus assays in isolated lymphocytes of 82 healthy donors and patients with head and neck cancer before radiotherapy. The parameters of background and radiation-induced DNA damage, rate of repair, and residual non-repaired damage were measured by comet assay, and the repair kinetics for every donor were computer-fitted to an exponential curve. The level of background DNA damage before irradiation measured by comet assay as well as the level of micronuclei were significantly higher in the head and neck cancer patient group than in the healthy donors, while the parameters of repair were widely scattered in both groups. Cancer patient group contained significantly more individuals, whose irradiated lymphocytes showed high DNA damage, low repair rate and high non-repaired DNA damage level. Lymphocytes of donors belonging to this subgroup showed significantly lower inhibition of cell cycle after irradiation.
2
Publication available in full text mode
Content available

Erythropoietin and the erythropoietin receptor, and drug resistance and progression of the neoplastic disease

88%
Leś D., Saduś-Wojciechowska M., Rutkowski T., Wygoda A., Składowski K.
|
EN
Preclinical studies conducted over the past 10 years have shown that EPO is not only a hormone that regulates erythropoiesis, a major growth factor, but also a cytoplasm with pleiotropic activity that also affects cancer cells. The expression of EPO and its receptor (EPOR) occurs in many cancers of various origins. The EPO/EPOR system is active in many cancer cells and is involved in the modification of molecular signaling pathways and the stimulation of growth, survival, motility and the ability to create metastases. EPO can also increase the resistance of cancer cells in vitro and in vivo to chemotherapy and radiotherapy.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.